<DOC>
	<DOCNO>NCT00832247</DOCNO>
	<brief_summary>This phase I clinical study evaluate feasibility , safety kinetics cellular therapy autologous bone marrow-derived mononuclear cell ( BMMC ) patient liver cirrhosis due virus C hepatitis . Another aim study liver tissue change induce BMMC presence . All patient moderate liver disfunction submit liver biopsy BMMC injection . The cell label 99mTc infused peripheral vein . Scintigraphy perform 24 hour infusion . Patients submit frequent clinical , laboratorial image evaluation one-year follow-up . A second liver biopsy do 3rd month infusion check histological , cellular molecular evolutive change .</brief_summary>
	<brief_title>Autologous Bone Marrow Mononuclear Cells Liver Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Chronic virus C hepatitis Liver cirrhosis Moderate liver disfunction Malignant disease Pregnancy Significant comorbidity Portal vein thrombosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Stem cell</keyword>
</DOC>